| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.09. | Secretive startup Treeline unveils first clinical candidates, $200M in new funding | ||
| 03.09. | Wave shares sink on new study results for RNA editing drug | ||
| 03.09. | Over 1,000 HHS employees call on RFK Jr. to step down | ||
| 03.09. | Novartis licenses RNA drugs in deal with China-based Argo | ||
| 02.09. | Amgen to invest $600M in new US center; Sanofi drug for ITP approved | ||
| 02.09. | Novartis thinks Arrowhead brain drug can succeed where others couldn't | ||
| 02.09. | Ionis looks to expand use of lipid-lowering drug after trial hits goal | ||
| 02.09. | Startup Corsera Health aims to bring preventive heart medicine to the masses | ||
| 02.09. | Turning aspirational innovations into tangible impacts | ||
| 28.08. | CDC panel to discuss COVID, hepatitis B shots in meeting next month | ||
| 28.08. | Novo strikes RNA drug deal with startup Replicate | ||
| 27.08. | FDA approves updated COVID boosters, but narrows use | ||
| 27.08. | Lilly says breast cancer drug extended survival in study | ||
| 27.08. | Amylyx drug comes up short; Sanofi names new CMO | ||
| 27.08. | Startup Wugen raises $115M for 'off-the-shelf' CAR-T | ||
| 26.08. | Lilly to submit obesity pill after hitting goal in third late-stage trial | ||
| 26.08. | Why an FDA decision on Stealth's Barth drug could ripple through the rare disease field | ||
| 26.08. | RNA drug from Regeneron, Alnylam succeeds in rare autoimmune disease trial | ||
| 25.08. | Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales | ||
| 25.08. | FDA suspends license for Valneva's chikungunya shot | ||
| 25.08. | AbbVie wagers more than $1B on Gilgamesh's psychedelic drug | ||
| 25.08. | Drugs from China are reshaping biotech. Track the licensing deals here. | ||
| 22.08. | FDA cancels adcomm on Biohaven drug; Catalent lays off staff | ||
| 21.08. | US, EU agree to terms of framework trade pact | ||
| 21.08. | FDA approves Ionis' hereditary angioedema drug |